FDA updates Merck's Covid-19 pill EUA and reaffirms it should only be used as a last resort
The FDA recently revised the EUA for Merck’s Covid-19 pill molnupiravir, explaining that it should only be used as a last line of defense if other treatments are available, including Pfizer’s pill Paxlovid, which posted 89% final efficacy results in the NEJM this week. Regulators also said other more highly efficacious infused drugs, including GlaxoSmithKline’s sotrovimab and Gilead’s remdesivir, should be used before molnupiravir.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
